header-frame
NOVEL GENE EDITING

Imagine A Better CRISPR

Boston-based Xenomics is a private biotechnology company that is advancing breakthroughs in genetics and biomanufacturing to combat major sustainability issues in food, energy, and health. At the heart of its technology is a next generation multi-site gene editing platform that enables biological advancement on an unparalleled scale. Xenomics combines genomics, synthetic biology, computational biology, and nanotechnology to advance the science needed to address humanity's most complex sustainability challenges—feeding, fueling, and healing society.

Xenomics’ team is working to build an unparalleled portfolio of gene-editing technologies designed to scalably modify cellular DNA with previously unattainable precision and sophistication. Its Harvard and MIT trained executive team includes leading global scientists with subspecialties in molecular biology, computational biology, data science, AI/ML, materials science, nanotechnology, nanofabrication, and engineering. In recent years, several technologies have attempted to address the challenges of creating large-scale genome engineering. Xenomics’ novel approach to single-cell genome engineering interfaces with the best of traditional benchtop molecular biology tools and existing infrastructure. By creating a model that dramatically reduces capital requirements and by leveraging high performance computing partnerships and talent, Xenomics’ technology has immense economic and technical advantages over existing approaches.

R&D

Core Technologies

WETWARE
SCALED GENOME EDITING
XenoArray™ generates millions unique cell lines within a search space of over 160 quadrillion combinations. The XenoArray™ is ideal for Gene Knock-Ins: Adding Genes, Enzymes & Pathways
  • Parallel gene edits with precision
  • Large multi-site gene inserts
  • Generating massive libraries of unique cell strains in parallel
  • Experiments that would have taken decades with legacy technologies can be performed in days
  • Genetic search space of over 160 quadrillion unique combinations of promoters, terminators, and/or genes
  • 1 to 150+ unique genes
HARDWARE
MICROFLUIDIC CELL HANDLING & ANALYSIS
We anticipate deploying a combination of commercially available equipment and custom microfluidic tooling to streamline lab processes, cell handling, and analysis.
  • Through a combination of commercially available equipment and custom microfluidic tooling, Xenomics anticipates having a system that can:
  • Ferment 10-15k strains in parallel for 72 hours per microfluidic chip
  • Assay 9k strains per day for results
  • Accelerate our design-build-test-learn model from weeks to days
SOFTWARE
BIOLOGICAL DATABASES, AND AI
Xenomics is working to streamline strain engineering by expanding upon previously published metabolomics databases and leveraging AI to improve our design-build-test-learn model.
  • Antibodies, enzymes, and other proteins with enhanced properties
  • Deep learning AI with atomic level precision
  • Target Databases:
  • Organisms library
  • DNA - Genomics
  • RNA - Transcriptomics
  • Proteins - Proteomics
  • Biochemical – Metabolomics
  • Biological Phenotype
OUR PEOPLE

Leadership Team

alternative

David Preiner

FOUNDER & CEO
  • Harvard University (Ext. BLA candidate) - Biology, Engineering Sciences, Nanotechnology
  • Boston Children's Hospital
  • State of MN
  • Bootstrapped 3 multi-million dollar startups
alternative

John Harrold, PhD

CO-FOUNDER & COO
  • MIT - Instructor Material Science & Engineering, Fellow
  • Harvard University - Physics Postdoc
  • Rutgers - PhD. B.S. B.A. Chemical Physics, Biochemistry
  • Led 30 person lab, 4 startups, 2 funded by NSF, 2 patents
alternative

Sophie Ni, PhD

CO-FOUNDER & CPO
  • MIT -PhD. Material Science, Engineering, Energy Applications
  • Nanyang Technological University - Engineering
  • Yamada, USA, managed US$83M P&L to deliver 43% growth in 3yrs
  • Startup co-founder
  • Forbes 30 under 30
alternative

Ryan Hubbard, MD

CO-FOUNDER & CMO
  • Mayo School of Graduate Medical Education - Resident Physician in Physical Medicine and Rehabilitation, Resident Internal Medicine
  • Georgetown University, M.D
  • Former Medical Instructor at Mayo Clinic (2016-2017)
  • 25+ Publications, Posters, and Oral Presentations
  • Sports Team Physician
alternative

Dan Kriznic, CPA, CA

CO-FOUNDER & CFO
  • Created Over $1 Billion in Enterprise Value
  • $700 Million in Exits
  • $243 Million in M&A Transactions
  • $175 Million in Financings
  • 9 Public Listings
alternative

Natasha Collins, CPA, CA

VP FINANCE
  • Over a Decade of Experience Advising Public and Private Companies
  • $180 Million of M&A Transactions
  • 2 Public Listings
alternative

Olivier Roussy Newton

VP BUSINESS DEVELOPMENT
  • Founder of Latent Capital
  • Co-Founder and President of Hive Blockchain
  • Raised Over $800 Million in the Past 2 Years
NEWSLETTER

Stay Updated With The Latest News

I've read and agree to Xenomics's written Privacy Policy and Terms Conditions
footer-frame